OrbiMed’s The Ensign Group ENSG Stock Holding History

OrbiMed’s Portfolio ENSG Stock Details ENSG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-549,680	Closed	-$11.6M	–	142
2016 Q1	$11.6M	Buy	549,680 +20,311	+4%	+$400K	0.12%	86
2015 Q4	$11.2M	Hold	529,369	–	–	0.1%	88
2015 Q3	$10.6M	Hold	529,369	–	–	0.11%	90
2015 Q2	$12.6M	Buy	+529,369	New	+$11.6M	0.11%	96

Other funds holding ENSG

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed's ENSG Position: Q2 2016 in Review

OrbiMed sold out of The Ensign Group (ENSG) in Q2 2016, closing a stake of 549,680 shares — an estimated $11.6M sold.

OrbiMed first reported a position in ENSG in Q2 2015 and held it in 4 quarters. The position peaked at $12.6M in Q2 2015. 168 funds tracked by Wall St. Rank hold ENSG as of Q2 2016.

OrbiMed reported no remaining The Ensign Group position as of Q2 2016 after selling out during the quarter.
OrbiMed sold 549,680 The Ensign Group shares in Q2 2016, an estimated $11.6M.
OrbiMed first reported a position in The Ensign Group in Q2 2015 and held it in 4 quarters.
OrbiMed's The Ensign Group position peaked at $12.6M in Q2 2015.
168 funds tracked by Wall St. Rank held The Ensign Group as of Q2 2016.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.